Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Aldesleukin + anti-KRAS G12D mTCR cells + Cyclophosphamide + Fludarabine|
Anti-KRAS G12D murine T-cell receptor (mTCR) cells are peripheral blood lymphocytes that have been transduced with a murine T-cell receptor that recognizes KRAS G12D, which may result in decreased growth of tumors harboring KRAS G12D (PMID: 26701267).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Aldesleukin||Proleukin||IL-2||Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|anti-KRAS G12D mTCR cells||Anti-KRAS G12D murine T-cell receptor (mTCR) cells are peripheral blood lymphocytes that have been transduced with a murine T-cell receptor that recognizes KRAS G12D, which may result in decreased growth of tumors harboring KRAS G12D (PMID: 26701267).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03745326||Phase Ib/II||Aldesleukin + anti-KRAS G12D mTCR cells + Cyclophosphamide + Fludarabine||Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients||Recruiting|